Illumina (NASDAQ:ILMN) dropped -0.75% or -1.05 points to trade at $139.05 per share. As per the latest trading data available, the net money flow stood at $21.72 million as the shares received $51.03 million in upticks and gave away $29.31 million in downticks. The final up/down ratio was at 1.74. On a weekly basis, the stock has seen a change of 1.46%.During the course of the session, the shares witnessed a block trade with an up/down ratio of 14.3. $20.51 million was the inflow in upticks and $1.43 million was the outflow in downticks. For the block trade, the net money flow was $19.07 million.
The stock has recorded a 20-day Moving Average of 2.34% and the 50-Day Moving Average is 3.75%. The company shares have dropped 36.53% in the past 52 Weeks. On July 20, 2015 The shares registered one year high of $242.37 and one year low was seen on May 4, 2016 at $127.1. The 50-day moving average is $140.77 and the 200 day moving average is recorded at $156.73. S&P 500 has rallied 1.93% during the last 52-weeks.
Illumina (NASDAQ:ILMN): The stock opened at $140.31 on Tuesday but the bulls could not build on the opening and the stock topped out at $140.87 for the day. The stock traded down to $137.53 during the day, due to lack of any buying support eventually closed down at $139.05 with a loss of -0.75% for the day. The stock had closed at $140.10 on the previous day. The total traded volume was 1,008,205 shares.
Currently the company Insiders own 1.6% of Illumina shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -16.59% . Institutional Investors own 98.52% of Illumina shares. During last six month period, the net percent change held by insiders has seen a change of -6.78%. On the companys insider trading activities,The director of Illumina Inc, Bowman A Blaine sold 5,000 shares at $135.17 on June 16, 2016. The Insider selling transaction had a total value worth of $675,850. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research, including de novo sequencing, genetic variation analysis, epigenetics and targeted screening, among others. It also provides products and services for other life sciences applied markets, such as agrigenomics. It also offers Clarity Run Manager, Clarity LIMS Silver and Clarity LIMS Gold.